Success Metrics

Clinical Success Rate
94.0%

Based on 47 completed trials

Completion Rate
94%(47/50)
Active Trials
2(3%)
Results Posted
21%(10 trials)
Terminated
3(5%)

Phase Distribution

Ph not_applicable
7
11%
Ph phase_2
7
11%
Ph phase_1
4
6%
Ph phase_3
24
37%
Ph phase_4
22
34%

Phase Distribution

4

Early Stage

7

Mid Stage

46

Late Stage

Phase Distribution64 total trials
Phase 1Safety & dosage
4(6.3%)
Phase 2Efficacy & side effects
7(10.9%)
Phase 3Large-scale testing
24(37.5%)
Phase 4Post-market surveillance
22(34.4%)
N/ANon-phased studies
7(10.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.4%

47 of 52 finished

Non-Completion Rate

9.6%

5 ended early

Currently Active

2

trials recruiting

Total Trials

65

all time

Status Distribution
Active(5)
Completed(47)
Terminated(5)
Other(8)

Detailed Status

Completed47
unknown7
Not yet recruiting3
Terminated3
Withdrawn2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
65
Active
2
Success Rate
94.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (6.3%)
Phase 27 (10.9%)
Phase 324 (37.5%)
Phase 422 (34.4%)
N/A7 (10.9%)

Trials by Status

completed4772%
not_yet_recruiting35%
active_not_recruiting12%
recruiting12%
withdrawn23%
terminated35%
suspended12%
unknown711%

Recent Activity

2 active trials
Showing 5 of 65
not_yet_recruitingphase_2

A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease

NCT07555054
active_not_recruitingphase_3

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850
completedphase_3

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03493685
completedphase_3

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

NCT00265642
terminatedphase_3

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

NCT05056727
View all 65 trials

Clinical Trials (65)

Showing 20 of 65 trialsScroll for more
NCT07555054Phase 2

A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease

Not Yet Recruiting
NCT03762850Phase 3

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Active Not Recruiting
NCT03493685Phase 3

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Completed
NCT00265642Phase 3

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

Completed
NCT05056727Phase 3

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Terminated
NCT03476603

Bariatric Surgery and Pharmacokinetics of Irbesartan

Recruiting
NCT01613118Phase 2

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Completed
NCT00152698Phase 3

Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia

Withdrawn
NCT00933231Phase 3

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

Completed
NCT06660940Phase 4

Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy

Not Yet Recruiting
NCT06635772Phase 2

A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

Not Yet Recruiting
NCT02597361Phase 3

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)

Completed
NCT05663073Phase 1

Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers

Completed
NCT05476354Phase 3

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

Completed
NCT05475665Phase 3

Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

Completed
NCT05688098Phase 1

Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers

Completed
NCT05243199Phase 4

Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

Completed
NCT04606563Phase 3

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated
NCT03934307Phase 1

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

Completed
NCT00535925Phase 4

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Completed

Drug Details

Intervention Type
DRUG
Total Trials
65